Desvenlafaxine Tablet, Extended Release
Product Images NDC 50090-6738

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 50090-6738). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Des Structure)

Chemical Structure (Des Structure)
Chemical structure of desvenlafaxine, showing a phenol group, a cyclohexanol ring, a dimethylaminoethyl side chain, associated with oxalic acid and a water molecule (hydrate). This structural formula represents the molecular composition of desvenlafaxine.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A forest plot showing the geometric mean ratios with 90% confidence intervals for Cmax and AUC pharmacokinetic parameters of Desvenlafaxine in various populations. Categories include renal impairment (mild, moderate, severe, ESRD), hepatic impairment (mild, moderate, severe), and population descriptions by gender and age groups (65-75 years, >75 years). The x-axis represents change relative to reference, ranging from 0.5 to 3.5.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A bar graph titled 'Geometric mean ratio (90% CI)' showing pharmacokinetic changes due to CYP3A4 inhibitors. It displays two data points for Ketoconazole: Cmax with a ratio close to 1.08 (range 1.00-1.17) and AUC with a ratio about 1.43 (range 1.38-1.49), plotted against a scale from 0.50 to 2.0 indicating change relative to reference.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A pharmacokinetic chart showing geometric mean ratios and 90% confidence intervals for drug interactions involving desvenlafaxine with substrates CYP2D6, CYP3A4, and combined CYP2D6 & CYP3A4. It compares Cmax and AUC values for drugs desipramine, midazolam, tamoxifen, and aripiprazole at various desvenlafaxine doses versus reference values.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A Kaplan-Meier curve chart depicting the estimated proportion of patients with relapse over time, measured in days from randomization. The graph compares Desvenlafaxine Extended-Release Tablets 50 mg (solid blue line) with placebo (dashed red line), showing lower relapse proportions for the Desvenlafaxine group throughout the study period up to 180 days.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A Kaplan-Meier curve displaying the estimated proportion of patients with relapse over time (days from randomization) for Desvenlafaxine Extended-Release Tablets compared to placebo. The x-axis represents time to relapse in days, and the y-axis shows the estimated proportion of patients with relapse as a percentage.*
FDA Label Image

Label Image (Lbl500906738)

Label Image (Lbl500906738)
Desvenlafaxine extended-release tablets 25 mg by A-S Medication Solutions. The label includes dosage instructions for oral use, storage conditions between 68 to 77 degrees Fahrenheit, and packaging of 30 tablets. The product NDC is 50090-6738.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.